A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor.

MLA

Stanne, Tara M., et al. “A Genome-Wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor.” Thrombosis and Haemostasis, vol. 118, no. 2, Feb. 2018, pp. 298–308. EBSCOhost, https://doi.org/10.1160/TH17-04-0249.

APA

Stanne, T. M., Olsson, M., Lorentzen, E., Pedersen, A., Gummesson, A., Gils, A., Jood, K., Engström, G., Melander, O., Declerck, P. J., & Jern, C. (2018). A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor. Thrombosis and Haemostasis, 118(2), 298–308. https://doi.org/10.1160/TH17-04-0249

Chicago

Stanne, Tara M, Maja Olsson, Erik Lorentzen, Annie Pedersen, Anders Gummesson, Ann Gils, Katarina Jood, et al. 2018. “A Genome-Wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor.” Thrombosis and Haemostasis 118 (2): 298–308. doi:10.1160/TH17-04-0249.